TY - JOUR

T1 - Association between atopic dermatitis and hypertension

T2 - a systematic review and meta-analysis

AU - Yousaf, M.

AU - Ayasse, M.

AU - Ahmed, A.

AU - Gwillim, E. C.

AU - Janmohamed, S. R.

AU - Yousaf, A.

AU - Patel, K. R.

AU - Thyssen, J. P.

AU - Silverberg, J. I.

N1 - Publisher Copyright: © 2021 British Association of Dermatologists

PY - 2022

Y1 - 2022

N2 - Background: Previous studies have found conflicting results about the association of atopic dermatitis (AD) with hypertension. Objectives: To determine whether AD and AD severity are associated with hypertension. Methods: A systematic review was performed of published studies in Ovid MEDLINE, Embase, Scopus, Web of Science, and GREAT (Global Resource for EczemA Trials) databases. At least two reviewers conducted title/abstract, full-text review and data extraction. Quality of evidence was assessed using the Newcastle–Ottawa Scale. Results: Fifty-one studies met the inclusion criteria and 19 had sufficient data for meta-analysis. AD was associated with higher odds of hypertension compared with healthy controls [increased in nine of 16 studies; pooled prevalence 16·4% vs. 13·8%; random-effects regression, pooled unadjusted odds ratio (OR) 1·16, 95% confidence interval (CI) 1·04–1·30], but lower odds of hypertension compared with psoriasis [decreased in five of eight studies; 15·4% vs. 24·8% (OR 0·53, 95% CI 0·37–0·76)]. In particular, moderate-to-severe AD was associated with hypertension compared with healthy controls [increased in four of six studies; 24·9% vs. 14·7% (OR 2·33, 95% CI 1·10–4·94)]. Hypertension was commonly reported as an adverse event secondary to AD treatments, particularly systemic ciclosporin A. Limitations include lack of longitudinal studies or individual-level data, and potential confounding. Conclusions: AD, particularly moderate-to-severe disease, was associated with increased hypertension compared with healthy controls, but with lower odds than for psoriasis.

AB - Background: Previous studies have found conflicting results about the association of atopic dermatitis (AD) with hypertension. Objectives: To determine whether AD and AD severity are associated with hypertension. Methods: A systematic review was performed of published studies in Ovid MEDLINE, Embase, Scopus, Web of Science, and GREAT (Global Resource for EczemA Trials) databases. At least two reviewers conducted title/abstract, full-text review and data extraction. Quality of evidence was assessed using the Newcastle–Ottawa Scale. Results: Fifty-one studies met the inclusion criteria and 19 had sufficient data for meta-analysis. AD was associated with higher odds of hypertension compared with healthy controls [increased in nine of 16 studies; pooled prevalence 16·4% vs. 13·8%; random-effects regression, pooled unadjusted odds ratio (OR) 1·16, 95% confidence interval (CI) 1·04–1·30], but lower odds of hypertension compared with psoriasis [decreased in five of eight studies; 15·4% vs. 24·8% (OR 0·53, 95% CI 0·37–0·76)]. In particular, moderate-to-severe AD was associated with hypertension compared with healthy controls [increased in four of six studies; 24·9% vs. 14·7% (OR 2·33, 95% CI 1·10–4·94)]. Hypertension was commonly reported as an adverse event secondary to AD treatments, particularly systemic ciclosporin A. Limitations include lack of longitudinal studies or individual-level data, and potential confounding. Conclusions: AD, particularly moderate-to-severe disease, was associated with increased hypertension compared with healthy controls, but with lower odds than for psoriasis.

U2 - 10.1111/bjd.20661

DO - 10.1111/bjd.20661

M3 - Review

C2 - 34319589

AN - SCOPUS:85115950401

VL - 186

SP - 227

EP - 235

JO - British Journal of Dermatology

JF - British Journal of Dermatology

SN - 0007-0963

IS - 2

ER -